Innate Pharma (IPHYF) Change in Working Capital (2019 - 2024)
Historic Change in Working Capital for Innate Pharma (IPHYF) over the last 6 years, with Q4 2024 value amounting to $41.8 million.
- Innate Pharma's Change in Working Capital rose 22119.74% to $41.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$85.3 million, marking a year-over-year decrease of 772.47%. This contributed to the annual value of -$41.8 million for FY2024, which is 22119.74% down from last year.
- Innate Pharma's Change in Working Capital amounted to $41.8 million in Q4 2024, which was up 22119.74% from -$72.4 million recorded in Q2 2024.
- Over the past 5 years, Innate Pharma's Change in Working Capital peaked at $41.8 million during Q4 2024, and registered a low of -$72.4 million during Q2 2024.
- Its 5-year average for Change in Working Capital is -$25.8 million, with a median of -$17.7 million in 2023.
- Examining YoY changes over the last 5 years, Innate Pharma's Change in Working Capital showed a top increase of 22119.74% in 2024 and a maximum decrease of 25897.2% in 2024.
- Over the past 5 years, Innate Pharma's Change in Working Capital (Quarter) stood at -$58.7 million in 2020, then skyrocketed by 80.73% to -$11.3 million in 2021, then fell by 12.82% to -$12.8 million in 2022, then tumbled by 170.69% to -$34.5 million in 2023, then surged by 221.2% to $41.8 million in 2024.
- Its Change in Working Capital stands at $41.8 million for Q4 2024, versus -$72.4 million for Q2 2024 and -$34.5 million for Q4 2023.